What does CRL stand for?

Complete Response Letter (US FDA)

This definition appears very rarely and is found in the following Acronym Finder categories:

Military and Government
Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Clinical Reference Library (database) Coalition for Responsible Lending CODA Readout Language Coherent Reverse Link Commercialization Readiness Level (NASA) Common Record Log Common Runtime Language Communications Research Laboratory (Japan) Community Reference Laboratory (Dorset, UK) Complete Reference Library (Mindscape)		Computer Research Lab COMSEC Requirements List Consciousness Research Laboratory Construction Reference Line (engineering drawings) Contribution sur les Revenus de Locations (French: Rental Income Contribution; taxes) Conventional Rotary Launcher Cooperative Research Laboratory Cost Readiness Level (project cost estimation; US NASA) Countermeasure Readiness Levels Country Request Live

Samples in periodicals archive:

Nasdaq: ABIO) today announced its planned next steps in response to the May 29, 2009 Complete Response Letter (CRL) from the U.

United States : ARCA biopharma provides financial and Gencaro NDA ...

Amgen said it is reviewing the FDA's message, called a complete response letter, and plans to respond soon.

FDA letter delays OK for Amgen bone drug Prolia

Received a second Complete Response Letter for Feraheme prior to its December 30, 2008 action date set by the FDA.

AMAG REPORTS $21.8 MILLION NET LOSS FOR 4TH QTR 2008

In its Complete Response Letter, the FDA raised no major issues or concerns around the safety of CIMZIATM or relating to Chemistry, Manufacturing and Controls (CMC) but did question the adequacy of one study design.

UCB INITIATES ADDITIONAL SHORT-TERM CLINICAL STUDY OF CIMZIA

Nasdaq: HGSI) today announced that it has received a Complete Response Letter from the U.

Human Genome Sciences Receives Complete Response Letter from FDA for ...

The FDA informed the company about its latest decision through the complete response letter for its marketing application for Lumizyme.

United states : FDA Denies Approval For Genzyme s Lumizyme Citing ...

In certain respects, the Complete Response Letter (request) appears to be inconsistent with the FDA's published final rule governing the development of new drugs when human efficacy studies are not ethical or feasible.

Human Genome sees FDA delay with anthrax treatment

The FDA's Center for Drug Evaluation and Research issues complete response letters when staff have finished reviewing all the experimental and other data in a new drug application and there are outstanding questions or issues that bar approval of the product.

FDA: More data needed on Glaxo nausea drug